Table 1. Demographic and clinicopathologic features of patients affected by HGPIN and undergoing transrectal prostate biopsy.
| Non antidiabetic Drug users (n: 456) | Metformin Users (n: 44) | Metformin Non-users (n: 51) | p value | ||
|---|---|---|---|---|---|
| Age (years), mean ± SD | 65.1±7.4 | 64.7±6.9 | 65.5±7.1 | NS | |
| Body Mass Index (kg/m2), mean ± SD | 26.7±4.6 | 27.2±3.9 | 33.8±3.1 | <0.001 | |
| Prostate volume (mL), mean ± SD | 38.4±12.7 | 36.9±11.3 | 37.8±12.3 | NS | |
| PSA level (ng/mL), mean ± SD | 11.3±8.6 | 10.8±8.8 | 11.1±8.3 | NS | |
| N° biopsy cores, median (range) | 21.2 (18-24) | 21.7 (18-24) | 21.4 (18-24) | NS | |
| Family history PCa, n(%) | NS | ||||
| No | 338(74.1) | 34(77.2) | 39(76.5) | ||
| Yes | 118(25.9) | 10(22.8) | 12(23.5) | ||
| DRE, n(%) | 181(39.7) | 17(38.6) | 20(39.2) | NS | |
| Prostate cancer, n(%) | 169(37.1) | 9(20.5) | 17(33.3) | <0.001 | |
| Positive biopsy cores, mean ± SD | 7.1±2.4 | 3.4±1.8 | 6.3±2.2 | <0.002 | |
| Cancer laterality, n(%) | <0.001 | ||||
| Unilateral | 112(66.3) | 7(77.7) | 11(64.7) | ||
| Bilateral | 57(33.7) | 2(22.3) | 6(35.3) | ||
| Biopsy Gleason score, n(%) | <0.001 | ||||
| ≤6 | 103(60.9) | 8(88.8) | 12(70.5) | ||
| ≥7 | 66(39.1) | 1(11.2) | 5(29.5) | ||
HGPIN = High grade prostatic intraepithelial neoplasia; PCa = prostate cancer; DRE = digital rectal examination; SD = standard deviation; PSA = prostate-specific antigen; NS = not significant.